Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.Mos4.HIV Regimens in HIV-1 Infected Adults
NCT03307915Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2018
- Primary completion
- Nov 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ad26.Mos4.HIV in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants With Solicited Local Adverse Events, Percentage of Participants With Solicited Systemic Adverse Events and 1 more. Started Mar 2018; status: completed.
02
Drugs
Ad26.Mos4.HIV
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03307915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307915.